Skip to main content

Advertisement

SpringerLink
Log in

2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15–17, 2016, Athens, Greece

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

This is the 2nd Symposium of a series organized annually. It aims to integrate tumor immunology basic research with results from most recent clinical trials based on the use of anti-cancer agents targeting immune system components.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abbreviations

ADO:

Adenosine

ccRCC:

Clear cell renal cell carcinoma

CIP:

CIMT Immunoguiding Program

CRC:

Colorectal carcinoma

CTCs:

Circulating tumor cells

EMT:

Epithelial to mesenchymal transition

ICD:

Immunogenic cell death

IEX:

Immune cell-derived exosomes

MET:

Mesenchymal to epithelial transition

TEX:

Tumor-derived exosomes

TKIs:

Tyrosine kinase inhibitors

Acknowledgements

We would like to thank all speakers for their participation.

Author information

Authors and Affiliations

  1. Section of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens, Panepistimioupolis, 15784, Athens, Greece

    Pinelopi Samara & Ourania Tsitsilonis

  2. Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece

    Athanasios Kotsakis & Vassilis Georgoulias

  3. Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece

    Athanasios Kotsakis & Vassilis Georgoulias

  4. Department of Internal Medicine II, Centre for Medical Research, University of Tübingen, 72072, Tübingen, Germany

    Graham Pawelec

  5. Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece

    Constantin N. Baxevanis

Authors
  1. Pinelopi Samara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Athanasios Kotsakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ourania Tsitsilonis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vassilis Georgoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Graham Pawelec
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Constantin N. Baxevanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PS, AK, and OT wrote the manuscript. VG, CNB and GP edited the manuscript.

Corresponding authors

Correspondence to Pinelopi Samara or Ourania Tsitsilonis.

Ethics declarations

Funding

We express our appreciation to the sponsors of the symposium: Amgen, Anabiosis, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, DEMO S.A. Pharmaceutical Industry, Enorasis, Genesis, Janssen, Lilly, Merck, Merck Sharp & Dohme Corp (MSD), Pfizer, Pierre Fabre, Roche Medical, Roche Marketing-Diagnostics, Sanofi and Specifar.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samara, P., Kotsakis, A., Tsitsilonis, O. et al. 2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15–17, 2016, Athens, Greece. Cancer Immunol Immunother 67, 153–159 (2018). https://doi.org/10.1007/s00262-017-2096-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-017-2096-6

Keywords

Search

Navigation